Complex Generics: Gottlieb Eyes FDA Policy Changes To Speed Approvals
US agency could reconsider requirement that instructions for use be same for branded and generic products, FDA Commissioner-nominee Scott Gottlieb suggests, while also leaving door open to statutory changes in Hatch-Waxman Act.
You may also be interested in...
Mylan received a “complete response” letter from FDA on its application for a generic version of GSK’s blockbuster Advair, offering scarce details on the reason why or possible length of the delay.
Former deputy commissioner will also likely push increased use of biomarkers and more flexibility in off-label communication, among other reforms.
FDA 'complete response' letter follows advisory committee's conclusion that the current naloxone approval standard is inadequate.